Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingStructural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic MacrocyclesTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferationCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studySensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell CulturesPharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disordersAre phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases.PASS Targets: Ligand-based multi-target computational system based on a public data and naïve Bayes approach.The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study.Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damageCM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaStructure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.Nitropropenyl benzodioxole, an anti-infective agent with action as a protein tyrosine phosphatase inhibitorEpidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.Ectokinases as novel cancer markers and drug targets in cancer therapy.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.1,8-Naphthalimide derivatives: new leads against dynamin I GTPase activity.EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivativesAnchor-based classification and type-C inhibitors for tyrosine kinases.Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance.Effects of FGFR2 kinase activation loop dynamics on catalytic activityA phosphotyrosine switch regulates organic cation transporters.Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.Dependence receptors and colorectal cancer.Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder.Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of β-catenin and of signaling interactions.Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs.Role of Oxidative Stress in Modulating Unfolded Protein Response Activity in Chronic Myeloid Leukemia Cell LinePanobinostat for the treatment of acute myelogenous leukemia.Engineering of synthetic gene circuits for (re-)balancing physiological processes in chronic diseases.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.Screening of the 'Stasis Box' identifies two kinase inhibitors under pharmaceutical development with activity against Haemonchus contortus.Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology.Tyrosine kinase inhibitor induced isolated pericardial effusion.
P2860
Q23923997-AD8901E1-DE2E-4EFA-A8E3-A447A12539A7Q27727987-77F93F99-509D-42B2-9873-47163D28F957Q28078154-2BC77D3E-45ED-4520-BF56-C770F88E5275Q28289188-B4633BCB-9FEE-4DE5-8266-9D4BC8A13A6DQ28545130-131EF9B7-B136-4714-86ED-F352A30A66B1Q28550991-0870B59B-CCE8-43D3-A2AA-AE249E3A97E1Q29048615-C29D9E21-25AC-4F98-91DB-2A6E3F6F3BF5Q30713425-A7A82F86-2AC1-4E7C-964F-D5FD89892E44Q30989605-22FC82DF-2C6C-4C99-9189-2FECC6C295C7Q33648593-9D6E9868-6914-489E-B5B0-3898E31D2A9DQ33675916-7DB509D3-CED7-4E63-9956-6DC3712E87DBQ33728096-60AF116F-820A-42DD-AD88-3D4F37EF5665Q33812445-6E3E271C-E43F-4EFD-9561-FE17DC633BDBQ33815443-003561F5-22B4-4639-BFA5-BABE23BDE1F8Q33947130-D6268972-D4BB-431A-892B-183FC0D05726Q35236798-726F83BA-1862-4181-AA3F-87AF21D85D9FQ35434188-7950CAA8-A54B-4A09-97CE-836456C834F6Q35676521-8F9962FE-6265-4A48-B5AB-06D9CAFAE3A8Q35729147-B4F52C66-18A8-4041-9DB5-791C8CC66B90Q35745479-C8FB320C-58DC-4DA1-BC9E-CBE0B4C35B6EQ36085847-BB2C93E1-4DDA-4250-B3D4-287E62B6C9C4Q36267581-75EA1CD8-FB09-44CB-887F-F588711ECC99Q36704820-9D8C1B32-20C2-40AF-8E58-52E72CE808D0Q36905854-C2B25AA2-BAFA-48A6-BEF4-B75DD40E8B4AQ37603214-B758540A-C156-4003-9C4F-3CB0F946285EQ38243917-1B825DA5-44A1-40EC-866D-2759C57FE156Q38607782-D37A8F78-08E2-4532-AC34-34156D08783AQ38740434-2CC25F4E-A023-420D-9E6F-1AB5F5251B7BQ38742560-4AFC603F-F96D-4BD8-AB66-B55DA6F870D9Q38761092-B5605680-66E7-4688-80AA-9840A6EFC321Q38818275-B11B0ABE-CB4D-4D77-B23C-837EE4E08D40Q38830627-49D72108-BEA9-41B6-91AA-A2A12CB97FB5Q38835113-6434598A-0DF0-43BF-9113-562208D26DE3Q38876131-21E5E8B3-3FAF-4711-99F0-4116F01571DEQ38922319-0361D94A-263B-4414-BC4F-32EF1B22C71FQ38976616-D87041B0-0627-40FD-B170-95A1113B64CEQ40146751-38208987-E3CC-4F3D-B802-DA34D83ACE67Q40529844-59578C2D-4EFE-4A4B-884C-10039A87BFCDQ41057002-179F8901-4A7A-4E42-A9B4-29AEB43A7591Q41351543-A1DCDA51-3925-40A8-ACAA-B38C08E86123
P2860
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
@en
type
label
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
@en
prefLabel
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
@en
P1476
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
@en
P2093
Alexander Levitzki
P304
P356
10.1146/ANNUREV-PHARMTOX-011112-140341
P577
2012-10-08T00:00:00Z